Predicting cognitive decline: Which is more useful, baseline amyloid levels or longitudinal change?

Area of Science:

• Neurology
• Radiology
• Biomarkers

Background:

• Early Alzheimer's disease (AD) detection via biomarkers is vital for therapeutic development.
• Positron Emission Tomography (PET) is established for detecting brain beta-amyloid (Aβ) plaques.
• Previous research indicates cross-sectional biomarkers predict cognitive decline, but longitudinal Aβ-PET's value remains unclear.

Purpose of the Study:

• To assess if baseline or longitudinal changes in 11C-Pittsburgh compound B (PiB) Aβ-PET predict cognitive decline in Alzheimer's disease.
• To compare the predictive power of single Aβ-PET scans versus tracking Aβ accumulation rates over time.

Main Methods:

• Analyzed data from 153 participants with PiB-PET scans and clinical assessments.
• Correlated baseline Aβ-PET levels with cognitive composite score changes.
• Examined the association between the rate of change in PiB-PET Aβ and cognitive decline.
• Investigated the influence of APOE ε4 carrier status on prediction.

Main Results:

• Higher baseline Aβ levels significantly predicted more rapid cognitive decline.
• No significant association was found between the rate of change in Aβ-PET and cognitive decline.
• APOE ε4 carrier status influenced the predictive ability of longitudinal Aβ-PET measures.

Conclusions:

• A single baseline Aβ-PET scan adequately predicts cognitive decline in Alzheimer's disease.
• Longitudinal monitoring of Aβ accumulation offers no additional benefit for predicting cognitive decline in amyloid-positive individuals.
• Findings support the sufficiency of baseline Aβ-PET for prognostic assessments in AD.